No Data
Stocks that moved the previous day part 2 Fit Easy, Osaka Yuka Kogyo, Hamee ETC.
Stock Name <Code> Closing Price on the 16th ⇒ Comparison with the previous day Kumiai Chemicals <4996> 734 -48 Viewed negatively regarding the profit guidance for the current period. Yamato HD <9064> 1757 -78 Yamato Transport has approached Japan Post to discuss stopping the delivery of small and thin packages. Kurazushi <2695> 3010 -130 Continuing to view the abolition of shareholder benefits negatively. Toho Titanium <5727> 942 -41 Daiwa Securities has lowered the Target Price. Odakyu Electric Railway <9007> 141
Emerging Markets stock digest: Dream Arts has made a significant rebound, HCH surges sharply.
Shannon (3976) surged 40 points to 569, hitting a new high for the year. After the close of trading on the 13th, Innovation announced that it would conduct a public offering for the company's Stocks and expressed its support, which is viewed positively. This public offering aims to make the company a consolidated subsidiary, but does not intend to delist the company's Stocks. It is expected that the company's Stocks will remain listed on the Tokyo Stock Exchange Growth Market even after the public offering is successful.
Hot Stocks Digest (First Half): River Eletech, Hamee, Danseisha ETC.
Osaka Oil Chemical Industry <4124>: 1920 yen. It is a limit-up Buy indication. Daiseki has announced plans to conduct a tender offer (TOB) aimed at complete acquisition. The company recommends participation in the TOB. The TOB price is 3201 yen, which is 2.1 times the closing price at the end of last week, and there is a prevailing movement aiming for a complete alignment with the TOB price. The TOB period is from December 16 to February 3, 2025. Improvements in recycling technology, strengthening responses to the Semiconductors industry, etc.
Bright Path --- Rising, partnered with the advanced company Cellistic for iPS cell therapy production.
An increase. The announcement of the signing of a process development and manufacturing contract for a Phase I clinical trial of iPS cell-derived BCMA CAR-NKT cells with Belgium's Cellistic is viewed positively. This partnership utilizes Cellistic's innovative three-dimensional cell culture manufacturing platform, Echo, to enable GMP-compliant clinical-scale manufacturing for the Phase I clinical trial of iPS cell-derived BCMA-targeted CAR-NKT cells in multiple myeloma.
Dream Arts, along with Classicom and others.
Below is the downward revision of VIS, with this period's operating profit and loss forecast at -0.214 billion yen, down from -0.144 billion yen. The approximately 0.268 billion yen gain from the sale of Nisso's subsidiary stocks is expected to be recorded as extraordinary profit. A revision of the performance forecast for Astroscale shows this period's project revenue forecast at 12 billion yen, down from 18 billion yen. A public tender offer by Shannon Innovation for Stock 3970 will be made at a price of 650 yen per share, and the listing is expected to be maintained after the public tender offer, with the remaining 25th new share rights.
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of IPSC-derived BCMA CAR-iNKT Cell
No Data